Glaxo Group Limited

David I Scopes

Michael D Dowle

David Middlemiss

Barry C Ross

Kevin S Cardwell

Torquil I Jack

Duncan B Judd

Stephen Paul Watson

John G Montana

Alexander W Oxford

John Bradshaw

David E Bays

Gordon H Phillipps

Colin David Eldred

Pritom Shah

Richard Storer

Norman F Hayes

Roger F Newton

Peter D Howes

Stuart Holman

Clive A Meerholz

Ann G Hayes

Martin Pass

Esme J Bailey

Stanley F Dyke

Andrew B McElroy

David J Belton

Richard C Cookson

David J Knight

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein the R groups are defined in the specification. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

Benzofuran derivatives

The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, solvates or non-toxic metabolically labile esters thereof where R.sup.1 represents a halogen atom; Ar represents the group ##STR2## R.sup.3 represents a C-linked tetrazolyl group; R.sup.4 and R.sup.5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a C.sub.1-6 alkyl group; and

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

Pyrazole containing benzofuran derivatives and pharmaceutical

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydroxy, C.sub.1-6 alkyl, C.sub.1-6 hydroxyalkyl, C.sub.1-6 carboxyalkyl, phenyl, oxo, amino, carboxy, amido, --NR.sub.4 COR.sub.5 (where R.sub.4 and R.sub.5 both represent C.sub.1-6 alkyl), optionally substituted methylidene or, together with the carbon atom to which it is attached, R.sub.1 forms a 5 or 6-membered ring containing one or more heteroatoms;

Spiropiperidine derivatives

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, unsubstituted or substituted C.sub.1-6 alkyl, halogen, --COR.sub.4 or --CO.sub.2 R.sub.4 (where R.sub.4 represents hydrogen or unsubstituted or substituted C.sub.1-6 alkyl);

Pharmaceutically useful furo[3,2-c]pyridines

Compounds are disclosed of formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and are C.sub.1-6 alkyl or C.sub.3-6 alkenyl; or --NR.sub.1 R.sub.2 forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, oxo, optionally substituted methylidene, --COR.sub.3 (where R.sub.6 represents C.sub.1-6 alkyl, OR.sub.4 or --NHR.sub.4, and R.sub.4 represents hydrogen, C.sub.1-6 alkyl, aryl, ar(C.sub.1-6)alkyl) or .dbd.NOR.sub.5 (where R.sub.5 represents C.sub.1-6 alkyl);

Morpholine derivatives, pharmaceutical compositions and use

Pharmaceutical compositions for combatting cancer comprising a compound of formula (I) ##STR1## (wherein R.sup.1 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl group;

Isoquinoline derivatives

Compounds of the formula: ##STR1## wherein R.sub.1, R.sub.3 and R.sub.4 each independently represents a hydrogen atom or a protecting group;

Imidazopyridayine derivatives having antiviral activity

Compounds of general formula (I): ##STR1## wherein R is a chlorine, bromine or iodine atom and physiologically acceptable salts thereof with bases of use as antiviral agents.

5-Halovinyl-2'-deoxyuridine derivatives

The present invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and bioprecursors thereof in which ##STR2## represents either ##STR3## R.sup.1 represents hydrogen, halogen, C.sub.1-4 alkoxy, hydroxy, alkyl, R.sup.4 CH(OH)--, cyano or R.sup.5 CONH--, R.sup.2 and R.sup.3, which may be the same or different, each represents a straight or branched chain alkyl group or alkenyl group or R.sup.2 and R.sup.3 may, together with the nitrogen atom to which they are attached, form a saturated heterocyclic ring containing from 5 to 7 members which may optionally contain an oxygen atom; R.sup.4 represents hydrogen or alkyl; and R.sup.5 represents hydrogen, alkyl or C.sub.1-4 alkoxy. The compounds have been shown to exhibit H.sub.1 -antagonist activity in standard pharmacological tests.

Growing community of inventors

Furneux Pelham, United Kingdom

David I Scopes